Abstract:G protein–coupled receptors (GPCRs) couple to heterotrimeric G proteins, comprised of α and β subunits, to convert extracellular signals into activation of intracellular signaling pathways. Canonically, GPCR-mediated activation results in the exchange of GDP for GTP on G protein α subunits (G α ) and the dissociation of G α -GTP and G protein β subunits (G β ), both of which can regulate a variety of signaling pathways. Hydrolysis of bound GTP by G α returns the protein to G α -GDP and allows reassociation with G β to reform the inactive heterotrimer. Naturally occurring mutations in G α have been found at conserved glutamine and arginine amino acids that disrupt the canonical G protein cycle by inhibiting GTP hydrolysis, rendering these mutants constitutively active. Interestingly, these dysregulated G α mutants are found in many different cancers due to their ability to sustain aberrant signaling without a need for activation by GPCRs. This review will highlight an increased recognition of the prevalence of such constitutively activating G α mutations in cancers and the signaling pathways activated. In addition, we will discuss new knowledge regarding how these constitutively active G α are regulated, how different mutations are biochemically distinct, and how mutationally activated G α are unique compared with GPCR-activated G α . Lastly, we will discuss recent progress in developing inhibitors directly targeting constitutively active G α mutants. SIGNIFICANCE STATEMENT Constitutively activating mutations in G protein α subunits (G α ) widely occur in and contribute to the development of many human cancers. To develop ways to inhibit dysregulated, oncogenic signaling by these mutant G α , it is crucial to better understand mechanisms that lead to constitutive G α activation and unique mechanisms that regulate mutationally activated G α in cells. The prevalence of activating mutations in G α in various cancers makes G α proteins compelling targets for the development of therapeutics.

The G protein Gαs acts as a tumor suppressor in sonic hedgehog signaling-driven tumorigenesis

The G Protein Α Subunit Gαs is a Tumor Suppressor in Sonic Hedgehog-Driven Medulloblastoma.

MEKK2 and MEKK3 Suppress Hedgehog Pathway-Dependent Medulloblastoma by Inhibiting GLI1 Function

An Epigenetic Switch Induced by Shh Signalling Regulates Gene Activation During Development and Medulloblastoma Growth

Smoothened-Independent Activation of Hedgehog Signaling by Rearranged During Transfection Promotes Neuroblastoma Cell Proliferation and Tumor Growth

Suppression of Growth and Migration by Blocking the Hedgehog Signaling Pathway in Gastric Cancer Cells

Cross regulation of signaling pathways in gastrointestinal stromal tumor (vol 16, pg 6770, 2018)

Inactivation of a Gα(s)-PKA tumour suppressor pathway in skin stem cells initiates basal-cell carcinogenesis

Epigenetic Silencing of a Ca2+-regulated Ras GTPase-activating Protein RASAL Defines a New Mechanism of Ras Activation in Human Cancers

Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation

Hedgehog signaling is controlled by Rac1 activity

GPCR-Hippo Signaling in Cancer

GPRC5A: an Emerging Biomarker in Human Cancer

Sonic Hedgehog Signaling in Organogenesis, Tumors, and Tumor Microenvironments

Phosphorylation of human glioma-associated oncogene 1 on Ser937 regulates Sonic Hedgehog signaling in medulloblastoma

Small-molecule modulators of the Sonic Hedgehog signaling pathway

Induction of Sonic Hedgehog Mediators by Transforming Growth Factor-Beta: Smad3-dependent Activation of Gli2 and Gli1 Expression in Vitro and in Vivo.

Sonic Hedgehog/Gli1 Signaling Pathway Inhibition Restricts Cell Migration and Invasion in Human Gliomas

Sonic Hedgehog Signaling in Thyroid Cancer

Gas1-Mediated Suppression of Hepatoblastoma Tumorigenesis

Going Rogue: Mechanisms, Regulation, and Roles of Mutationally Activated G{alpha} in Human Cancer